Insider Selling: Atara Biotherapeutics, Inc. (ATRA) CEO Sells 4,400 Shares of Stock

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) CEO Isaac E. Ciechanover sold 4,400 shares of Atara Biotherapeutics stock in a transaction on Wednesday, December 13th. The stock was sold at an average price of $14.65, for a total transaction of $64,460.00. Following the transaction, the chief executive officer now directly owns 743,675 shares of the company’s stock, valued at $10,894,838.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) traded down $0.15 during trading hours on Thursday, hitting $14.55. The stock had a trading volume of 165,509 shares, compared to its average volume of 230,102. Atara Biotherapeutics, Inc. has a fifty-two week low of $11.80 and a fifty-two week high of $23.00.

Atara Biotherapeutics (NASDAQ:ATRA) last released its earnings results on Thursday, November 9th. The biotechnology company reported ($1.02) earnings per share for the quarter, missing the consensus estimate of ($0.97) by ($0.05). equities research analysts predict that Atara Biotherapeutics, Inc. will post -4 EPS for the current year.

Several large investors have recently added to or reduced their stakes in ATRA. Vanguard Group Inc. lifted its position in shares of Atara Biotherapeutics by 10.9% during the first quarter. Vanguard Group Inc. now owns 831,925 shares of the biotechnology company’s stock worth $17,095,000 after purchasing an additional 81,634 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of Atara Biotherapeutics by 4.3% during the first quarter. Geode Capital Management LLC now owns 173,639 shares of the biotechnology company’s stock worth $3,568,000 after purchasing an additional 7,231 shares during the last quarter. Morgan Stanley lifted its position in shares of Atara Biotherapeutics by 147.6% during the first quarter. Morgan Stanley now owns 175,058 shares of the biotechnology company’s stock worth $3,597,000 after purchasing an additional 104,369 shares during the last quarter. Schwab Charles Investment Management Inc. lifted its position in shares of Atara Biotherapeutics by 5.9% during the first quarter. Schwab Charles Investment Management Inc. now owns 79,580 shares of the biotechnology company’s stock worth $1,636,000 after purchasing an additional 4,446 shares during the last quarter. Finally, Bank of Montreal Can bought a new stake in shares of Atara Biotherapeutics during the second quarter worth $834,000. Institutional investors and hedge funds own 85.61% of the company’s stock.

Several research analysts have commented on ATRA shares. Goldman Sachs Group reaffirmed a “neutral” rating and set a $20.00 price objective on shares of Atara Biotherapeutics in a research note on Friday, October 6th. Jefferies Group reaffirmed a “buy” rating and set a $30.00 price objective on shares of Atara Biotherapeutics in a research note on Thursday, August 31st. Canaccord Genuity reaffirmed a “buy” rating and set a $47.00 price objective on shares of Atara Biotherapeutics in a research note on Monday, September 11th. Zacks Investment Research lowered shares of Atara Biotherapeutics from a “buy” rating to a “hold” rating in a research note on Monday, August 28th. Finally, ValuEngine upgraded Atara Biotherapeutics from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st. Three equities research analysts have rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $24.40.

TRADEMARK VIOLATION NOTICE: “Insider Selling: Atara Biotherapeutics, Inc. (ATRA) CEO Sells 4,400 Shares of Stock” was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this story on another website, it was illegally copied and republished in violation of US and international trademark & copyright legislation. The correct version of this story can be read at https://www.dispatchtribunal.com/2017/12/14/insider-selling-atara-biotherapeutics-inc-atra-ceo-sells-4400-shares-of-stock-2.html.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.

Insider Buying and Selling by Quarter for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply